Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment
Addiction, 06/29/09
Bell J et al. - Buprenorphine was safer during induction. Despite shorter retention in treatment, buprenorphine maintenance was not associated with higher risk of death.
Methods- First entrants to treatment between June 2002 and June 2006 were identified from the PHDAS database.
- Retention in treatment was compared between methadone and buprenorphine.
- Names were linked to the NDI database, and `good matches' were identified.
- Deaths were classified as occurring during induction, maintenance and either post-methadone or post-buprenorphine, depending on the latest episode of treatment prior to death.
- The numbers of inductions into treatment, of total person-years spent in each treatment, and person-years post-methadone or buprenorphine, were calculated.
- Risk of death in different periods, and different treatments, was analysed using Poisson regression.
- A total of 5992 people entered their first episode of treatment—3349 (56%) on buprenorphine, 2643 on methadone.
- Median retention was significantly longer in methadone (271 days) than buprenorphine (40 days).
- During induction, the risk of death was lower for buprenorphine (relative risk=0.114, 95% confidence interval=0.002-0.938, P=0.02, Fisher's exact test).
- Risk of death was lowest during treatment, significantly higher in the first 12 months after leaving both methadone and buprenorphine.
- Beyond 12 months after leaving treatment, risk of death was non-significantly higher than during treatment.
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09
Today in Other Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
Today in Substance Abuse...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Adverse health effects of non-medical cannabis use
The Lancet, 10/19/09
Improving Clinical Outcomes in Treating Heroin Dependence: Randomized, Controlled Trial of Oral or Implant Naltrexone
Archives of General Psychiatry, 10/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


